ストックスクリーナーアプリを入手
311.10
1.54%
4.02
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Equities Analysts Issue Forecasts for MDGL FY2025 Earnings - MarketBeat
MDGL (Madrigal Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales - MSN
MDGL (Madrigal Pharmaceuticals) Change In Working Capital : $7.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
MDGL (Madrigal Pharmaceuticals) Quick Ratio : 5.93 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH - Seeking Alpha
Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - Simply Wall St
MDGL (Madrigal Pharmaceuticals) Net Income From Continuing Operations : $-518.67 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) EV-to-EBITDA : -10.99 (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Capex-to-Operating-Cash-Flo - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Earnings Yield % : N/A% (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) 3-Year Book Growth Rate : 9.60% (As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Debt-to-Asset : 0.11 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals executive sells shares worth $120,847 - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 442 Shares - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells $461,789.49 in Stock - MarketBeat
Madrigal Pharmaceuticals exec sells $461,789 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals general counsel sells $75,734 in stock By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals general counsel sells $75,734 in stock - Investing.com India
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.4%Should You Buy? - MarketBeat
Madrigal Pharmaceuticals exec sells $461,789 in stock - Investing.com India
Shannon T. Kelley Sells 277 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals executive sells shares worth $120,847 By Investing.com - Investing.com Canada
Madrigral Pharmaceuticals gains amid takeover speculation - MSN
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week - MSN
Madrigal Reports Robust 2024 Performance and Plans for Growth - MSN
Why Madrigal Pharmaceuticals (MDGL) Stock is Moving Today - GuruFocus.com
What is HC Wainwright's Forecast for MDGL FY2024 Earnings? - MarketBeat
Hennion & Walsh Asset Management Inc. Reduces Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Trend Tracker for (MDGL) - Stock Traders Daily
Madrigal CEO touts 'amazing' sales success of new MASH drug, but stock slumps - The Business Journals
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 14.4%Here's What Happened - MarketBeat
Why Madrigal Pharmaceuticals Stock Is Sinking Today - MSN
Madrigal Pharmaceuticals Enters Oversold Territory (MDGL) - Nasdaq
HC Wainwright Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: Rezdiffra success drives stock outlook By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals' SWOT analysis: Rezdiffra success drives stock outlook - Investing.com India
MDGL Stock Dips Amid Preliminary 2024 Results Release - GuruFocus.com
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra - The Manila Times
Madrigal's Rezdiffra Achieves $180M Sales in First Year as Groundbreaking MASH Treatment - StockTitan
Madrigal Pharmaceuticals' SWOT analysis: stock poised for growth amid NASH market potential - Investing.com India
Madrigal Pharmaceuticals’ SWOT analysis: stock poised for growth amid NASH market potential - Investing.com Nigeria
Madrigal Pharmaceuticals' SWOT analysis: stock poised for growth amid NASH market potential By Investing.com - Investing.com South Africa
1.88%
5.20%
大文字化:
|
ボリューム (24 時間):